article thumbnail

Can technology help diversify clinical trials?

pharmaphorum

Teams and Zoom became the backbone of communication and firms embraced new ways of working. Liam Johnstone has six years of toxicology experience working across regulators in the UK, developing expertise in medicine, consumer product and agrochemical safety whilst working at the MHRA, OPSS and HSE, respectively.

article thumbnail

Omnibus Spending Law: Provisions Will Bolster Medicines Supply Chain Insights and Advanced Manufacturing Technologies

Quality Matters

Leveraging insights from data on USP standards distribution and usage at more than 22,000 locations worldwide and 40+ external data sets, USP launched the Medicine Supply Map in 2021 to provide an early-warning capability for supply chain vulnerabilities.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Pharmaceutical Continuous Manufacturing: Regulatory landscape in the spotlight at USP workshop

Quality Matters

That way…we can do our best to communicate with you about how to best prepare a submission.” The ETP facilitates “early engagement” with FDA “before and during submission and assessment” of industry regulatory applications involving an AMT such as PCM, Fisher explained.

article thumbnail

Pathbreakers: The journey of first generics

Pharmaceutical Technology

In recent years, first generics have improved patient access to essential treatments and offered affordable treatment options for patients with multiple sclerosis, asthma, heart disease, diabetes, and even the flu. Please check your email to download the Report.

article thumbnail

What a mild recession could mean for small biotechs in 2023

Pharmaceutical Technology

Joy Polefrone, the executive director of the organization, says it aims to build a cluster of partners who are capable of manufacturing generic medicines. The US Department of Commerce’s Economic Development Administration (EDA) awarded the organization $52.9 million as part of the Build Back Better Regional Challenge.

article thumbnail

The Future of Generic Drug Development for Emerging Markets: Opportunities and Challenges

Drug Patent Watch

Generic drugs offer a viable solution, providing high-quality treatments at a fraction of the cost of branded medicines. Regulatory frameworks, intellectual property laws, and quality control standards can vary significantly across different regions, making it difficult for generic manufacturers to navigate the complex landscape.